RO 7105705 - TO BE DELETED

Drug Profile

RO 7105705 - TO BE DELETED

Latest Information Update: 07 Jul 2016

Price : $50

At a glance

  • Originator Genentech
  • Class Antidementias; Monoclonal antibodies
  • Mechanism of Action Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 01 Jun 2016 Phase-I clinical trials in Alzheimer's disease in USA (IV, Infusion and SC) (NCT02820896)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top